NASDAQ:VNDA - Vanda Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$20.80 -0.15 (-0.72 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$20.95
Today's Range$20.70 - $21.15
52-Week Range$11.90 - $21.25
Volume292,400 shs
Average Volume600,047 shs
Market Capitalization$1.08 billion
P/E Ratio-59.29
Dividend YieldN/A
Beta0.89
Vanda Pharmaceuticals logoVanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Canada, Europe, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Receive VNDA News and Ratings via Email

Sign-up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:VNDA
CUSIP92165910
Phone202-734-3400

Debt

Debt-to-Equity RatioN/A
Current Ratio3.93
Quick Ratio3.91

Price-To-Earnings

Trailing P/E Ratio-59.29
Forward P/E Ratio-416.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$165.08 million
Price / Sales6.57
Cash FlowN/A
Price / CashN/A
Book Value$2.92 per share
Price / Book7.12

Profitability

EPS (Most Recent Fiscal Year)($0.35)
Net Income$-15,560,000.00
Net Margins-2.84%
Return on Equity-3.06%
Return on Assets-2.07%

Miscellaneous

Employees273
Outstanding Shares52,110,000
Market Cap$1,078.69

Vanda Pharmaceuticals (NASDAQ:VNDA) Frequently Asked Questions

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its quarterly earnings data on Wednesday, May, 2nd. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.17) by $0.23. The biopharmaceutical company earned $43.59 million during the quarter, compared to analysts' expectations of $43.30 million. Vanda Pharmaceuticals had a negative return on equity of 3.06% and a negative net margin of 2.84%. The company's revenue for the quarter was up 16.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.11) EPS. View Vanda Pharmaceuticals' Earnings History.

When is Vanda Pharmaceuticals' next earnings date?

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Vanda Pharmaceuticals.

What price target have analysts set for VNDA?

6 analysts have issued 1-year price objectives for Vanda Pharmaceuticals' shares. Their forecasts range from $18.00 to $27.00. On average, they anticipate Vanda Pharmaceuticals' stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 10.6% from the stock's current price. View Analyst Ratings for Vanda Pharmaceuticals.

What is the consensus analysts' recommendation for Vanda Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Vanda Pharmaceuticals' key competitors?

Who are Vanda Pharmaceuticals' key executives?

Vanda Pharmaceuticals' management team includes the folowing people:
  • Dr. Mihael H. Polymeropoulos, Founder, Pres, CEO & Director (Age 58)
  • Mr. James Patrick Kelly, Exec. VP, CFO, Treasurer & Sec. (Age 52)
  • Mr. Gunther Birznieks, Sr. VP of Bus. Devel. (Age 49)
  • Mr. Gian Piero Reverberi, Sr. VP & Chief Commercial Officer (Age 52)
  • Dr. Deepak Phadke Ph.D., VP of Manufacturing (Age 68)

Has Vanda Pharmaceuticals been receiving favorable news coverage?

News stories about VNDA stock have been trending somewhat negative on Saturday, Accern reports. The research firm identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vanda Pharmaceuticals earned a media sentiment score of -0.17 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 48.00 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Foundry Partners LLC (0.10%), Fox Run Management L.L.C. (0.05%), Xact Kapitalforvaltning AB (0.02%) and Hartford Investment Management Co. (0.02%). Company insiders that own Vanda Pharmaceuticals stock include Gunther Birznieks, James E Flynn, James Patrick Kelly, Mihael Hristos Polymeropoulos and Richard L Gulino. View Institutional Ownership Trends for Vanda Pharmaceuticals.

Which institutional investors are selling Vanda Pharmaceuticals stock?

VNDA stock was sold by a variety of institutional investors in the last quarter, including Foundry Partners LLC. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Gunther Birznieks, James Patrick Kelly and Mihael Hristos Polymeropoulos. View Insider Buying and Selling for Vanda Pharmaceuticals.

Which institutional investors are buying Vanda Pharmaceuticals stock?

VNDA stock was bought by a variety of institutional investors in the last quarter, including Xact Kapitalforvaltning AB, Hartford Investment Management Co. and Fox Run Management L.L.C.. View Insider Buying and Selling for Vanda Pharmaceuticals.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vanda Pharmaceuticals' stock price today?

One share of VNDA stock can currently be purchased for approximately $20.80.

How big of a company is Vanda Pharmaceuticals?

Vanda Pharmaceuticals has a market capitalization of $1.08 billion and generates $165.08 million in revenue each year. The biopharmaceutical company earns $-15,560,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. Vanda Pharmaceuticals employs 273 workers across the globe.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE N.W. SUITE 300 E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]


MarketBeat Community Rating for Vanda Pharmaceuticals (NASDAQ VNDA)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  347 (Vote Outperform)
Underperform Votes:  181 (Vote Underperform)
Total Votes:  528
MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe VNDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.